In the first prospective pivotal trials, visual gains of +13.9–18.3 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were achieved after 52 weeks while receiving between 8 and 9.8 anti-vascular endothelial growth factor (VEGF) injections [3–7]. The gene discussed is VEGFA; the disease is diabetic retinopathy.